Please login to the form below

Not currently logged in
Email:
Password:

apceth names Ulrike Verzetnitsch as chief technical officer

She joins from Takeda, with immediate effect

edit-apceth-Ulrike-VerzetnischCell therapy company apceth has appointed Ulrike Verzetnitsch in the newly created role of chief technical officer.

In the position, Verzetnitsch will lead apceth's production facilities and operations and continue the expansion of its fee-for-service GMP manufacturing business.

Commenting on the appointment, Christine Guenther, CEO of apceth, said: “apceth has recently started phase II of the world's first clinical trial with genetically modified mesenchymal stem cells in cancer indications and is simultaneously increasing its manufacturing capacity and capabilities as a CMO. It is therefore a very exciting time for us to welcome Ulrike to the team.

“Her experience will complement our management team and help drive apceth forward.”

She joins from Takeda, where she was head of the production unit based in Singen, Germany. Prior to that, Verzetnitsch held the role of director of production at Baxter, where she focused on strategic tasks in the final container operation of vaccines and plasma-based and recombinant products.

As part of her role, she gained experience in the manufacturing of products for worldwide distribution in compliance with the FDA, EMEA, Japanese and other guidelines.

28th April 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics